Neuropathic Pain Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032
Description
Persistence Market Research has recently released a comprehensive report on the worldwide market for neuropathic pain. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neuropathic pain market from 2025 to 2032.
Key Insights:
Neuropathic pain refers to chronic pain resulting from damage to the somatosensory nervous system and is commonly associated with conditions such as diabetes, cancer, spinal cord injuries, postherpetic neuralgia, and multiple sclerosis. The market encompasses a range of pharmacological treatments-including anticonvulsants, antidepressants, opioids, topical agents, and others-administered through various routes. The market serves hospitals, clinics, retail pharmacies, and outpatient settings worldwide, with demand driven by improved diagnostics, aging populations, and increasing prevalence of chronic diseases that cause nerve damage.
Market Growth Drivers:
The global neuropathic pain market is driven by the rising global prevalence of diabetes, cancer, and other chronic conditions that elevate nerve damage risk. Diabetic neuropathy, in particular, represents a major indication given the high incidence of diabetes worldwide. Improvements in diagnostic capabilities and expanded access to pain management therapies contribute to greater treatment uptake. Furthermore, a shift toward non‑opioid alternatives due to concerns around opioid addiction and regulatory pressures supports demand for safer, more effective therapeutic options.
Market Restraints:
Despite positive growth prospects, the neuropathic pain market faces challenges due to severe side effects associated with some pain management medications and the high cost of branded therapies, particularly in developing regions. These financial and safety concerns can hinder market adoption and limit access to advanced treatments in cost‑sensitive markets.
Market Opportunities:
There is a significant unmet need for disease‑modifying treatments that target underlying pathophysiological mechanisms of nerve damage rather than solely alleviating pain symptoms. Advances in neurobiology, gene therapy, and biomarker‑driven strategies present opportunities to develop novel therapies aimed at nerve regeneration and long‑term outcomes. Personalized pain management approaches and combination therapies also offer growth potential.
Key Questions Answered in the Report:
Leading players in the global neuropathic pain market focus on expanding product portfolios, advancing clinical research, and forming strategic collaborations to enhance competitiveness. Firms emphasize development of targeted therapies with better efficacy and safety profiles, while partnerships with healthcare providers and research institutions support innovations and market penetration. Emphasis on patient‑centric care, personalized medicine, and combination treatment strategies is key to capturing market share in a competitive landscape.
Key Companies Profiled:
By Drug Class:
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
- Neuropathic Pain Market Size (2025E): USD9.1 Billion
- Projected Market Value (2032F): USD 13.2 Billion
- Global Market Growth Rate (CAGR 2025 to 2032): 5.5%
Neuropathic pain refers to chronic pain resulting from damage to the somatosensory nervous system and is commonly associated with conditions such as diabetes, cancer, spinal cord injuries, postherpetic neuralgia, and multiple sclerosis. The market encompasses a range of pharmacological treatments-including anticonvulsants, antidepressants, opioids, topical agents, and others-administered through various routes. The market serves hospitals, clinics, retail pharmacies, and outpatient settings worldwide, with demand driven by improved diagnostics, aging populations, and increasing prevalence of chronic diseases that cause nerve damage.
Market Growth Drivers:
The global neuropathic pain market is driven by the rising global prevalence of diabetes, cancer, and other chronic conditions that elevate nerve damage risk. Diabetic neuropathy, in particular, represents a major indication given the high incidence of diabetes worldwide. Improvements in diagnostic capabilities and expanded access to pain management therapies contribute to greater treatment uptake. Furthermore, a shift toward non‑opioid alternatives due to concerns around opioid addiction and regulatory pressures supports demand for safer, more effective therapeutic options.
Market Restraints:
Despite positive growth prospects, the neuropathic pain market faces challenges due to severe side effects associated with some pain management medications and the high cost of branded therapies, particularly in developing regions. These financial and safety concerns can hinder market adoption and limit access to advanced treatments in cost‑sensitive markets.
Market Opportunities:
There is a significant unmet need for disease‑modifying treatments that target underlying pathophysiological mechanisms of nerve damage rather than solely alleviating pain symptoms. Advances in neurobiology, gene therapy, and biomarker‑driven strategies present opportunities to develop novel therapies aimed at nerve regeneration and long‑term outcomes. Personalized pain management approaches and combination therapies also offer growth potential.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the neuropathic pain market globally?
- Which drug classes and indications are dominating market demand?
- How are treatment innovations and non‑opioid approaches shaping the competitive landscape?
- Who are the key players in the neuropathic pain market, and what strategies are they employing?
- What are the emerging trends and future prospects in the global neuropathic pain market?
Leading players in the global neuropathic pain market focus on expanding product portfolios, advancing clinical research, and forming strategic collaborations to enhance competitiveness. Firms emphasize development of targeted therapies with better efficacy and safety profiles, while partnerships with healthcare providers and research institutions support innovations and market penetration. Emphasis on patient‑centric care, personalized medicine, and combination treatment strategies is key to capturing market share in a competitive landscape.
Key Companies Profiled:
- Almatica
- Vertex Pharmaceuticals Incorporated
- Azurity Pharmaceuticals, Inc.
- Pfizer Inc.
- Viatris Inc.
- Supernus Pharmaceuticals, Inc.
- Novartis AG
- Accord Healthcare
- Focus Health Group
- Amneal Pharmaceuticals LLC
- Abbott
- Teva Pharmaceutical Industries Ltd.
By Drug Class:
- Anticonvulsants
- Tricyclic Antidepressants
- SNRI’s
- Topical Anesthetics
- Opioids
- Diabetic Neuropathy
- Post‑herpetic Neuralgia
- Spinal Cord Injury
- Oral
- Parenteral
- Topical
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- North America
- Europe
- East Asia
- South Asia and Oceania
- Middle East and Africa
- Latin America
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
191 Pages
- 1. Executive Summary
- 1.1. Global Neuropathic Pain Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. COVID-19 Impact Analysis
- 2.4. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Disease Epidemiology
- 3.2. Value Chain Analysis
- 3.3. Technology Assessment
- 3.4. Product Adoption / Usage Analysis
- 3.5. Recent Product Approvals & Launches
- 3.6. Key Market Players
- 3.7. Regulatory Landscape
- 3.8. PESTLE Analysis
- 3.9. Porter’s Five Force Analysis
- 4. Global Neuropathic Pain Market Outlook
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
- 4.3. Global Neuropathic Pain Market Outlook: Drug Class
- 4.3.1. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
- 4.3.2. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 4.3.2.1. Tricyclic Anti-Depressants
- 4.3.2.2. Anticonvulsants
- 4.3.2.3. SNRI's
- 4.3.2.4. Topical Anesthetics
- 4.3.2.5. Opioids
- 4.3.2.6. Others
- 4.3.3. Market Attractiveness Analysis: Drug Class
- 4.4. Global Neuropathic Pain Market Outlook: Indication
- 4.4.1. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
- 4.4.2. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 4.4.2.1. Diabetic Neuropathy
- 4.4.2.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 4.4.2.3. Post-Herpetic Neuralgia (PHN)
- 4.4.2.4. Trigeminal Neuralgia
- 4.4.2.5. Spinal Cord Injury-Associated Neuropathy
- 4.4.2.6. Phantom Limb Pain
- 4.4.2.7. Multiple Sclerosis-Associated Neuropathy
- 4.4.2.8. Others
- 4.4.3. Market Attractiveness Analysis: Indication
- 4.5. Global Neuropathic Pain Market Outlook: Route of Administration
- 4.5.1. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2023
- 4.5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 4.5.2.1. Oral
- 4.5.2.2. Topical
- 4.5.2.3. Parenteral
- 4.5.3. Market Attractiveness Analysis: Route of Administration
- 4.6. Global Neuropathic Pain Market Outlook: Distribution Channel
- 4.6.1. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
- 4.6.2. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 4.6.2.1. Hospital Pharmacies
- 4.6.2.2. Retail Pharmacies
- 4.6.2.3. Online Pharmacies
- 4.6.3. Market Attractiveness Analysis: Distribution Channel
- 5. Global Neuropathic Pain Market Outlook: Region
- 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
- 5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Region, 2024-2032
- 5.2.1. North America
- 5.2.2. Latin America
- 5.2.3. Europe
- 5.2.4. East Asia
- 5.2.5. South Asia and Oceania
- 5.2.6. Middle East & Africa
- 5.3. Market Attractiveness Analysis: Region
- 6. North America Neuropathic Pain Market Outlook
- 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 6.1.1. By Country
- 6.1.2. By Drug Class
- 6.1.3. By Indication
- 6.1.4. By Route of Administration
- 6.1.5. By Distribution Channel
- 6.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 6.2.1. U.S.
- 6.2.2. Canada
- 6.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 6.3.1. Tricyclic Anti-Depressants
- 6.3.2. Anticonvulsants
- 6.3.3. SNRI's
- 6.3.4. Topical Anesthetics
- 6.3.5. Opioids
- 6.3.6. Others
- 6.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 6.4.1. Diabetic Neuropathy
- 6.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 6.4.3. Post-Herpetic Neuralgia (PHN)
- 6.4.4. Trigeminal Neuralgia
- 6.4.5. Spinal Cord Injury-Associated Neuropathy
- 6.4.6. Phantom Limb Pain
- 6.4.7. Multiple Sclerosis-Associated Neuropathy
- 6.4.8. Others
- 6.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 6.5.1. Oral
- 6.5.2. Topical
- 6.5.3. Parenteral
- 6.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies
- 6.6.3. Online Pharmacies
- 6.7. Market Attractiveness Analysis
- 7. Europe Neuropathic Pain Market Outlook
- 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 7.1.1. By Country
- 7.1.2. By Drug Class
- 7.1.3. By Indication
- 7.1.4. By Route of Administration
- 7.1.5. By Distribution Channel
- 7.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 7.2.1. Germany
- 7.2.2. France
- 7.2.3. U.K.
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 7.3.1. Tricyclic Anti-Depressants
- 7.3.2. Anticonvulsants
- 7.3.3. SNRI's
- 7.3.4. Topical Anesthetics
- 7.3.5. Opioids
- 7.3.6. Others
- 7.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 7.4.1. Diabetic Neuropathy
- 7.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 7.4.3. Post-Herpetic Neuralgia (PHN)
- 7.4.4. Trigeminal Neuralgia
- 7.4.5. Spinal Cord Injury-Associated Neuropathy
- 7.4.6. Phantom Limb Pain
- 7.4.7. Multiple Sclerosis-Associated Neuropathy
- 7.4.8. Others
- 7.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 7.5.1. Oral
- 7.5.2. Topical
- 7.5.3. Parenteral
- 7.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies
- 7.6.3. Online Pharmacies
- 7.7. Market Attractiveness Analysis
- 8. East Asia Neuropathic Pain Market Outlook
- 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 8.1.1. By Country
- 8.1.2. By Drug Class
- 8.1.3. By Indication
- 8.1.4. By Route of Administration
- 8.1.5. By Distribution Channel
- 8.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 8.2.1. China
- 8.2.2. Japan
- 8.2.3. South Korea
- 8.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 8.3.1. Tricyclic Anti-Depressants
- 8.3.2. Anticonvulsants
- 8.3.3. SNRI's
- 8.3.4. Topical Anesthetics
- 8.3.5. Opioids
- 8.3.6. Others
- 8.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 8.4.1. Diabetic Neuropathy
- 8.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 8.4.3. Post-Herpetic Neuralgia (PHN)
- 8.4.4. Trigeminal Neuralgia
- 8.4.5. Spinal Cord Injury-Associated Neuropathy
- 8.4.6. Phantom Limb Pain
- 8.4.7. Multiple Sclerosis-Associated Neuropathy
- 8.4.8. Others
- 8.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 8.5.1. Oral
- 8.5.2. Topical
- 8.5.3. Parenteral
- 8.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies
- 8.6.3. Online Pharmacies
- 8.7. Market Attractiveness Analysis
- 9. South Asia & Oceania Neuropathic Pain Market Outlook
- 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 9.1.1. By Country
- 9.1.2. By Drug Class
- 9.1.3. By Indication
- 9.1.4. By Route of Administration
- 9.1.5. By Distribution Channel
- 9.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 9.2.1. India
- 9.2.2. Indonesia
- 9.2.3. Thailand
- 9.2.4. Singapore
- 9.2.5. ANZ
- 9.2.6. Rest of South Asia & Oceania
- 9.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 9.3.1. Tricyclic Anti-Depressants
- 9.3.2. Anticonvulsants
- 9.3.3. SNRI's
- 9.3.4. Topical Anesthetics
- 9.3.5. Opioids
- 9.3.6. Others
- 9.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 9.4.1. Diabetic Neuropathy
- 9.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 9.4.3. Post-Herpetic Neuralgia (PHN)
- 9.4.4. Trigeminal Neuralgia
- 9.4.5. Spinal Cord Injury-Associated Neuropathy
- 9.4.6. Phantom Limb Pain
- 9.4.7. Multiple Sclerosis-Associated Neuropathy
- 9.4.8. Others
- 9.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 9.5.1. Oral
- 9.5.2. Topical
- 9.5.3. Parenteral
- 9.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies
- 9.6.3. Online Pharmacies
- 9.7. Market Attractiveness Analysis
- 10. Latin America Neuropathic Pain Market Outlook
- 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 10.1.1. By Country
- 10.1.2. By Drug Class
- 10.1.3. By Indication
- 10.1.4. By Route of Administration
- 10.1.5. By Distribution Channel
- 10.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 10.2.1. Brazil
- 10.2.2. Mexico
- 10.2.3. Rest of Latin America
- 10.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 10.3.1. Tricyclic Anti-Depressants
- 10.3.2. Anticonvulsants
- 10.3.3. SNRI's
- 10.3.4. Topical Anesthetics
- 10.3.5. Opioids
- 10.3.6. Others
- 10.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 10.4.1. Diabetic Neuropathy
- 10.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 10.4.3. Post-Herpetic Neuralgia (PHN)
- 10.4.4. Trigeminal Neuralgia
- 10.4.5. Spinal Cord Injury-Associated Neuropathy
- 10.4.6. Phantom Limb Pain
- 10.4.7. Multiple Sclerosis-Associated Neuropathy
- 10.4.8. Others
- 10.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 10.5.1. Oral
- 10.5.2. Topical
- 10.5.3. Parenteral
- 10.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies
- 10.6.3. Online Pharmacies
- 10.7. Market Attractiveness Analysis
- 11. Middle East & Africa Neuropathic Pain Market Outlook
- 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 11.1.1. By Country
- 11.1.2. By Drug Class
- 11.1.3. By Indication
- 11.1.4. By Route of Administration
- 11.1.5. By Distribution Channel
- 11.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2024-2032
- 11.2.1. GCC Countries
- 11.2.2. Egypt
- 11.2.3. South Africa
- 11.2.4. Northern Africa
- 11.2.5. Rest of Middle East & Africa
- 11.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2024-2032
- 11.3.1. Tricyclic Anti-Depressants
- 11.3.2. Anticonvulsants
- 11.3.3. SNRI's
- 11.3.4. Topical Anesthetics
- 11.3.5. Opioids
- 11.3.6. Others
- 11.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2024-2032
- 11.4.1. Diabetic Neuropathy
- 11.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 11.4.3. Post-Herpetic Neuralgia (PHN)
- 11.4.4. Trigeminal Neuralgia
- 11.4.5. Spinal Cord Injury-Associated Neuropathy
- 11.4.6. Phantom Limb Pain
- 11.4.7. Multiple Sclerosis-Associated Neuropathy
- 11.4.8. Others
- 11.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2024-2032
- 11.5.1. Oral
- 11.5.2. Topical
- 11.5.3. Parenteral
- 11.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2024-2032
- 11.6.1. Hospital Pharmacies
- 11.6.2. Retail Pharmacies
- 11.6.3. Online Pharmacies
- 11.7. Market Attractiveness Analysis
- 12. Competition Landscape
- 12.1. Market Share Analysis, 2024
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping by Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Almatica
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Sources
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Vertex Pharmaceuticals Incorporated
- 12.3.3. Azurity Pharmaceuticals, Inc.
- 12.3.4. Pfizer Inc.
- 12.3.5. Viatris Inc.
- 12.3.6. Supernus Pharmaceuticals, Inc.
- 12.3.7. Novartis AG
- 12.3.8. Accord Healthcare
- 12.3.9. Focus Health Group
- 12.3.10. ABneal Pharmaceuticals LLC.
- 12.3.11. Abbott
- 12.3.12. Teva Pharmaceutical Industries Ltd.
- 12.3.13. Others
- 13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
